Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide significantly improved median metastasis-free survival (MFS) by two years compared to placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
J&J’s apalutamide shows strength in non-metastatic prostate cancer
